Trials / Terminated
TerminatedNCT00195325
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTI-237 |
Timeline
- Start date
- 2005-08-01
- First posted
- 2005-09-19
- Last updated
- 2007-03-26
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00195325. Inclusion in this directory is not an endorsement.